Combivent Respimat (ipratropium/albuterol metered spray inhalation) / Boehringer Ingelheim - LARVOL DELTA

Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients (PRNewswire) - "Boehringer Ingelheim's new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company's inhalers is now available. The program applies to all Boehringer Ingelheim inhalers, including: Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray. Spiriva HandiHaler (tiotropium bromide inhalation powder). Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray. Spiriva Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray. Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. Striverdi Respimat (olodaterol) Inhalation Spray."

Pricing • Asthma • Chronic Obstructive Pulmonary Disease

"17/ For example, @Boehringer released #Combivent (albuterol-ipratropium) in 1996 and #Combivent Respimat in 2011 w/ a total of 35 years of patent protection on these products lasting through 2030. #devicehop" (@wbfeldman)

Strategies to conserve salbutamol pressurized metered-dose inhaler stock levels amid COVID-19 drug shortage. (PubMed, Drugs Ther Perspect) - "Other short-acting muscarinic antagonists (SAMAs), such as ipratropium pMDI, and combinations of SABA/SAMA, such as Combivent Respimat, are also starting to have supply issues. These strategies include reprocessing used or expired pMDIs, using intravenous salbutamol and other short acting inhalers when available, and prescribing maintenance inhalers to prevent over usage of salbutamol pMDIs. We also highlight the important role of physicians and pharmacists in optimizing medication therapies to ensure adequate supplies."

Journal • Asthma • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases